University of California, Irvine
uci.eduTotal trials
462
Active
113
Phase 3
9
Total enrollment
537,050
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 76 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Topiramate | — | — | — | — | — | 2 | |
| Nortriptyline + Topiramate | — | — | — | — | — | 2 | |
| 4% Chlorhexidine Gluconate | — | — | — | — | — | 1 | |
| 2% Mupirocin | — | — | — | — | — | 1 | |
| Soap Without Antiseptic Properties | — | — | — | — | — | 1 | |
| Phentermine | — | — | — | — | — | 1 | |
| Neostigmine Injectable Solution | — | — | — | — | — | 1 | |
| Sugammadex | — | — | — | — | — | 1 | |
| Oral furosemide | — | — | — | — | — | 1 | |
| Intravenous furosemide | — | — | — | — | — | 1 | |
| Suzetrigine | — | — | — | — | — | 1 | |
| Nortriptyline | — | — | — | — | — | 1 | |
| Paroxetine | — | — | — | — | — | 1 | |
| Verapamil | — | — | — | — | — | 1 | |
| Lovenox | — | — | — | — | — | 1 | |
| Estring Vaginal Product | — | — | — | — | — | 1 | |
| Vagifem | — | — | — | — | — | 1 | |
| Estrace 0.01% Vaginal Cream | — | — | — | — | — | 1 | |
| Tau PET scan using MK-6240 | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | 4 | |||
| Nivolumab | — | — | — | — | 3 | ||
| Trastuzumab | — | — | — | — | 4 | ||
| Cyclophosphamide | — | — | — | — | 3 | ||
| Cabozantinib | — | — | — | — | 3 | ||
| Riluzole | — | — | — | — | — | 2 | |
| Fludarabine | — | — | — | — | 2 | ||
| Paclitaxel | — | — | — | — | — | 2 | |
| Carboplatin | — | — | — | — | 4 | ||
| Bevacizumab | — | — | — | — | — | 3 | |
| Abemaciclib | — | — | — | — | — | 2 | |
| Fulvestrant | — | — | — | — | — | 2 | |
| Nelfinavir | — | — | — | — | — | 1 | |
| Fianlimab | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Letermovir | — | — | — | — | — | 1 | |
| Melphalan | — | — | — | — | — | 1 | |
| Ipilimumab | — | — | — | — | — | 1 | |
| Mirtazapine | — | — | — | — | — | 1 | |
| Leucovorin | — | — | — | — | — | 1 | |
| Fluorouracil | — | — | — | — | — | 1 |
36 more active programs hidden
Next readouts
- 2023-11
- 2023-11-25
- 2024-06-30
- 2025-06-27
- 2025-11-30
- 2026-06
- 2026-06-01
- 2026-06-01
- 2026-06-14
- 2026-07
Top conditions
- Breast Cancer13
- Cancer9
- Port Wine Stain9
- Prostate Cancer9
- Lung Cancer6
- Colorectal Cancer6
- Ovarian Cancer6
- Port-Wine Stain6
Frequently asked questions about University of California, Irvine
- How many clinical trials does University of California, Irvine have on ClinicalTrials.gov?
- University of California, Irvine is listed as the lead sponsor on 462 clinical trials in ClinicalTrials.gov, 113 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of California, Irvine's trials are in Phase 3?
- 9 of University of California, Irvine's trials are in Phase 3, spread across 76 active drug programs.
- What therapeutic areas does University of California, Irvine focus on?
- University of California, Irvine's most-studied conditions on ClinicalTrials.gov are Breast Cancer, Cancer, Port Wine Stain, Prostate Cancer, Lung Cancer.
- When are University of California, Irvine's next clinical trial readouts?
- University of California, Irvine has 10 upcoming primary-completion readouts tracked here; the soonest is “Phase II Breast Ca Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab or Bevacizumab”, expected around 2023-11.